NVIDIA and TSMC Bring AI Into Fabs to Advance Semiconductor Design and ManufacturingNVIDIA today announced that TSMC, the world’s leading semiconductor company, is using NVIDIA accelerated computing and AI to advance semiconductor design and manufacturing.News Summary:NVIDIA CUDA-X libraries and AI models are accelerating TSMC workloads across lithography, transistor and process simulation, advanced process control and fab operations optimization. TSMC is using NVIDIA Metropolis and NVIDIA TAO Toolkit to advance automated defect inspection with vision AI, improving detection of nanometer-scale defects while reducing repeated labeling and retraining.TAIPEI, Taiwan, June 01, 2026 (GLOBE NEWSWIRE) — NVIDIA GTC Taipei — NVIDIA today announced that TSMC, the world’s leading semiconductor company, is using NVIDIA accelerated...

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment optionBasel, 1 June 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA)....

Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs. Targeted alpha therapy is emerging as an important area of development in precision oncology. Alpha-emitting isotopes deliver highly concentrated radiation over a very short distance, destroying cancer cells with remarkable precision with limited exposure to surrounding healthy...

BNP PARIBAS PRESENTS THE GROWTH STRATEGY OF ITS COMMERCIAL BANK IN BELGIUM (CPBB) AND RAISES ITS PROFITABILITY TARGETS TO 22% PRE-TAX RONE IN 2028 AND 25% IN 2030 PRESS RELEASE Paris, 01 June 2026 BNP Paribas Commercial and Personal Banking in Belgium (CPBB) is at the heart of the CPBS roadmap and a key contributor to Commercial & Personal Banking in the Eurozone (CPBE) within BNP Paribas Group, with #1 market position across its core segments: Affluent & Mass Market banking[i], Private Banking & Wealth Management[ii], Corporate Banking[iii]. CPBB also benefits from a unique distribution model combining scale and flexibility, with a largely variable cost base. CPBB is moving forward with a strategic roadmap to capture profitable growth. It will reinforce its three leading client franchises by strengthening its offering...

The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension.Allschwil, Switzerland – June 01, 2026Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia’s dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data were presented by Prof. Markus Schlaich at the 35th Congress of the European Society of Hypertension (ESH). The oral presentation, entitled “Effect of the Dual Endothelin Receptor Antagonist Aprocitentan on Albuminuria”, underscores the role of endothelin pathway inhibition not only in blood pressure control, but also in addressing kidney-related...

Krulli KasvuhooneKasvuhoone_South entrance_by CobeOn 29 May 2026, AS Merko Ehitus Eesti, part of the AS Merko Ehitus group, and AS Krulli Kvartal signed a construction agreement for the construction of the main building of the quarter, a commercial building named Kasvuhoone in Tallinn at Volta 1f. The contract covers the restoration of the Krulli Quarter’s historic industrial building and its conversion into a modern business and innovation centre with a gross floor area of over 17,000 square metres. The development of Kasvuhoone, integrates solutions for several heritage protection constraints, high architectural and public space standards, as well as principles of reuse and a low carbon footprint. A five-storey wooden tower rising above the old limestone walls will become a landmark of the Krulli Quarter. Kasvuhoone brings...

New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III extension study up to week 108 and Phase II data in systemic lupus erythematosus will be presentedBasel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases. “Novartis is committed to shaping the future of immunology. From small molecules to biologics and CAR-T cell therapy, our pioneering science is focused on where we can have the greatest impact on patient outcomes,” said Angelika Jahreis, Global Head, Immunology...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and sporesAllschwil, Switzerland – June 1, 2026Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia’s synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort. Results from healthy participants...

NVIDIA Open Source Agent Tools and Skills for Physical AINVIDIA releases a major open source collection of physical AI agent skills and tools spanning NVIDIA Omniverse, Cosmos, Alpamayo and Metropolis for robotics, autonomous vehicles, vision AI and industrial digital twins.News Summary:NVIDIA releases a major open source collection of physical AI agent skills and tools spanning NVIDIA Omniverse, Cosmos, Alpamayo and Metropolis for robotics, autonomous vehicles, vision AI and industrial digital twins. New physical AI skills turn complex physical AI training, evaluation and deployment workflows into repeatable, optimized and agent-executable instructions. Industry leaders including Agile Robots, Cadence, Dassault Systèmes, Delta Electronics, Foxconn, Pegatron, PTC, Siemens, Synopsys and TSMC are using NVIDIA physical AI tools...

NVIDIA Isaac GR00T Reference Humanoid RobotNVIDIA today announced the NVIDIA Isaac GR00T Reference Humanoid Robot, the first open humanoid robot reference design built on NVIDIA Jetson Thor™ and the NVIDIA Isaac GR00T open development platform.News Summary:NVIDIA announces an open humanoid robot reference design built on the NVIDIA Isaac GR00T platform, combining a Unitree H2 Plus humanoid robot, Sharpa five-fingered hands for dexterous manipulation, NVIDIA Jetson Thor onboard compute for advanced reasoning and control, and NVIDIA Isaac GR00T open software and models. The Isaac GR00T development platform — spanning data capture and generation to robot model evaluation and deployment — helps researchers and developers accelerate humanoid development workflows.  Leading research institutions including Ai2, ETH Zurich, Stanford...